INTRODUCTION
Baicalin (BA) is a major flavonoid constituent (Figure 1) found in the traditional Chinese medicinal herb Baikal skullcap (Scutellaria baicalensis Georgi), known as "Huang qin" in China and "Ogon" in Japan, which has been widely used for the treatment of various diseases such as pneumonia, hepatitis, and diarrhea (Huang et al., 1986) . Previous studies have demonstrated that BA possesses a wide range of pharmacological and biological activities such as anti-inflammatory, anti-allergic, antimicrobial, antioxidant, and anti-tumor properties (Zhang et al., 2003) . Its anti-inflammatory activity has been estimated in various animal models of acute and chronic inflammation (Kubo et al., 1984; Lin and Shieh, 1996; Zeng et al., 2007) . Evidence shows that its anti-inflammatory actions are associated with the suppression of functions of various inflammatory cells and inhibition the production of pro-inflammatory mediators such as TNF-α, interleukin (IL)-1, and PGE 2 (Chung et al., 1995; Krakauer et al., 2001) . Recently, it is reported that BA can inhibit the proliferation of mouse T-lymphocytes stimulated with various mitogens and arrest lymphocytes in G 0 /G 1 phase (Li et al., 2009 ). The results of these studies indicate that BA may have pronounced immunoregulatory properties, although the underlying mechanisms still remain to be fully elucidated.
Dendritic cells (DCs) are potent antigen-presenting cells that initiate lymphocyte activation (Banchereau and Steinman, 1998; Banchereau et al., 2000 
MATERIALS AND METHODS

REAGENTS
Baicalin (purity >99%) was purchased from National Institute for the Control of Pharmaceutical and Biological Products, China. Lipopolysaccharide (LPS) and RPMI-1640 were purchased from Sigma (St Louis, MO, USA). Fetal calf serum was purchased from GIBCO-BRL (Gland Island, NY, USA). Recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 were purchased from R&D System (Minneapolis, MN, USA). Fluorescein-5-isothiocyanate (FITC)-anti-mouse CD11c, PE-antimouse CD80, PE-Cy5-anti-mouse CD86, and anti-murine Fc receptor monoclonal antibodies were purchased from PharMingen (San Diego, CA, USA). The J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyan ine iodide (JC-1) was purchased from Molecular Probes (Eugene, OR, USA). Annexin V-FITC Apoptosis Detection kit was purchased from Keygen Biotech. Co., Ltd (Nanjing, China). All other chemicals used were of the highest grade available commercially.
CULTURE OF BONE MARROW-DERIVED DCs
Bone marrow-derived DCs were generated according to the method described previously (Inaba et al., 1992) with some modification. In brief, BM cells were flushed from the femurs and tibiae of female C57BL/6 mice (purchased from Shanghai SLAC Laboratory Animal Co., Ltd, Shanghai, China), filtered through a Falcon 100-μm nylon cell strainer (BD Labware), and depleted of red blood cells by 5 min incubation in ACK lysis buffer (0.15 M NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.4). Whole BM cells were plated in six-well plates (BD Labware) in RPMI-1640 supplemented with 10% FCS, GM-CSF (10 ng/ml), and IL-4 (10 ng/ml), and incubated at 37°C and 5% CO 2 . Three days later, the floating cells (mostly granulocytes) were removed, and the adherent cells were replenished with fresh medium containing GM-CSF and IL-4. Non-adherent and loosely adherent cells were harvested on day 6 as immature DC (typically contained >90% cells expressing CD11c and MHC II on the surface, as determined by flow cytometry). To stimulate DCs maturation, LPS (500 ng/ml) was added to the culture on day 5 as indicated. For analysis of BA effects on DC development, BA (2-50 μM) was added on day 3.
PHENOTYPIC MARKER ANALYSIS
Dendritic cells harvested on day 6 were washed and suspended in fluorescence-activated cell-sorting analysis (FACS) Buffer (phosphate buffered saline containing 0.1% bovine serum albumin and 0.01% NaN 3 ), and stained with the fluorescence-conjugated monoclonal antibodies recognizing CD11c, CD80, or CD86 in the presence of anti-murine Fc receptor monoclonal antibody as described previously (Zhang et al., 2004) . Samples were analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, USA) with the CellQuest software package.
IL-12 ASSAY
Interleukin-12 levels in the supernatants of BMDCs were determined by ELISA kits (Bender MedSystems, Vienna, Austria), according to the manufacturer's instructions.
DETECTION OF APOPTOSIS
The annexin V-FITC binding and propidium iodide (PI) staining assay were used to assess apoptosis of DCs as described previously (Koopman et al., 1994) . 1 × 10 6 cells were stained with the annexin V-FITC and PI provided with the Annexin V-FITC Apoptosis Detection kit (purchased from Keygen Biotech. Co., Ltd, Nanjing, China), according to the manufacturer's instructions. Stained cells were analyzed via a FACSCalibur and the CellQuest software (Becton Dickinson, USA). Annexin V positive cells were determined as apoptosis cells.
ASSAY FOR MITOCHONDRIAL MEMBRANE POTENTIAL
Mitochondrial membrane potential (∆ψ m ) was determined by flow cytometry using J-aggregate forming lipophilic cationic probe JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimida zolcarbocyanine iodide) following the manufacturer's protocol (Molecular Probes, Eugene, OR, USA), and as described previously (Cossarizza et al., 1993) . In brief, JC-1 was dissolved in dimethyl sulfoxide (5 mg/ml), and 50 μl were added to 10 ml of medium. 5 × 10 5 DCs were incubated with 2 ml of medium containing JC-1 for 15 min at 37°C and then washed twice with PBS. Cells were then resuspended in 0.5 ml of PBS and analyzed on a FACSCalibur (Becton Dickinson, USA) to detect green fluorescence at excitation/emission wavelengths of 485/530 nm and red fluorescence at excitation/emission wavelengths of 550/595 nm. Since JC-1 exhibits potential-dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green (∼525 nm) to red (∼590 nm), mitochondrial depolarization is indicated by a decrease in the red-to-green fluorescence-intensity ratio.
STATISTICS
All data were expressed as the mean values ± SD. Differences between groups were examined for statistical significance using the Student's t-test. A value of p < 0.05 was considered statistically significant.
RESULTS
EFFECTS OF BA ON DC MATURATION AND APOPTOSIS
The effect of BA on DCs was initially investigated in BM cell cultured for 6 days with GM-CSF and IL-4, which generates mainly BMDCs. BA (0-50 μM) was added on day 3, and LPS (500 ng/ml) was added on day 5 to stimulate DC maturation. The surface expressions of CD11c, CD80, and CD86 on BA-treated and -untreated DCs were examined by flow cytometry, and levels of IL-12 in the supernatants were measured by ELISA. The results demonstrated that more than 90% of non-adherent and loosely adherent cells A significant degree of apoptosis was detected in the BA-treated DC, as shown by an increased phosphatidyl exposure using annexin V-FITC ( Figure 2E ).
COMPARISON OF BA-INDUCED APOPTOSIS IN IMMATURE AND MATURE DC
We further compared BA-induced apoptosis in mature DCs and immature DCs. In this experiment, the day-6 DCs stimulated with LPS were used as mature DCs, because they highly expressed CD80/ CD86 and secreted high level of IL-12. In comparison, the day-6 DCs without stimulation by LPS were used as immature DCs. Mature and immature DCs were treated with 50 μM of BA for different time were CD11c
+ cells, and LPS stimulation markedly up-regulated the expression of CD80 and CD86 within the CD11c + population (Figures 2A,D) and induced substantial release of IL-12 to the culture supernatants (Figure 2C) , suggesting most cells harvested on day 6 were DCs. BA inclusion showed no effects on the upregulation of CD80/CD86 expression in response to the stimulation of LPS (Figures 2A,D) , but resulted in a concentration-dependent reduction of total numbers of viable CD11c + cells recovered on day 6 of culture ( Figure 2B) , and significantly suppressed the release of IL-12 to culture supernatants ( Figure 2C) . To examine whether BA reduced cell recovery by inducing cell death, apoptosis in the day-6 DCs was further assessed by FACS after annexin V/PI staining. (24-72 h) or with graded concentrations of BA (12.5-50 μM) for 48 h, then cellular apoptosis was assessed by FACS after annexin V/PI staining. BA-induced apoptosis in both mature and immature DCs in time-and dose-dependent way and immature DCs were more sensitive for BA-induced apoptosis than mature DC (Figures 3 and 4) .
EFFECTS OF BA ON MITOCHONDRIAL MEMBRANE POTENTIAL IN DCs
One of the early critical events in apoptosis is the loss/disruption of mitochondrial membrane potential (∆ψ m ) in the cells, which eventually causes the initiation and activation of apoptotic cascades. We sought to determine whether BA-treatment had any effect on the ∆ψ m in DCs using JC-1 staining. Figure 5 shows treatment of DCs with BA resulted in dose-dependent increase in the proportion of green fluorescence-positive cells (indicating loss of mitochondrial membrane potential) in both immature DCs and mature DCs, and higher proportion of green fluorescence-positive cells were detected in BA-treated immature DCs. These results confirm that BA induced the loss of ∆ψ m in DCs, which is more profound in immature DCs than in mature DCs.
DISCUSSION
This is the first study demonstrating that BA can evoke apoptosis in DCs. BA addition into cytokine-driven cultures of murine BM cells resulted in a reduced recovery of CD11c + cells and less production of IL-12, but shown no effects on the up-regulation of CD80/ CD86 expression in response to the stimulation of LPS, suggesting BA has no influence on DC maturation, but may induce DC apoptosis. The fact that BMDCs underwent strong apoptosis in the presence of BA in a time-and dose-dependent manner further confirmed its pro-apoptotic activity. Interestingly, immature DCs homeostasis is disturbed as DCs become activated and promote the clonal expansion of antigen-specific lymphocytes. Shortly after the peak of the response, controlled induction of apoptosis, of both DCs and lymphocytes, restores homeostasis. This process is critical to ensure protective immunity and avoid lymphoid neoplasia and autoimmunity (Hildeman et al., 2007) . While decreased apoptosis can cause an overabundance of lymphocytes and possibly autoimmune reactions, enhanced apoptosis can result in lymphocyte depletion and immunosuppression, so that the possibility to interfere with regulatory mechanisms of apoptosis, aiming either to block or to enhance it at different time points, represents a promising approach for the development of new immunomodulatory therapies (Rashedi et al., 2007) . Previous studies have demonstrated that BA can inhibit the proliferation of T-lymphocytes (Li et al., 2009 ) and induce apoptosis in Jurkat T cells (Ueda et al., 2002) . Here, we provide evidence that DCs may also primary target of BA for immunomodulation.
Traditionally, the development of immunosuppressive drugs and understanding of their action has been focused on lymphocytes. Many classical immunosuppressive agents, such as cyclosporine A, rapamycin, dexamethasone, and 1,25(OH)2D3, were found to modulate immune responses by inhibiting lymphocyte proliferation or promoting their apoptosis. However, recent evidence indicates that these agents interfere with immune responses at the earliest stage, targeting key functions of DCs (Hackstein and Thomson, 2004) . For example, 1,25(OH)2D3 inhibits the differentiation and maturation of human DCs, abrogates the capacity of mature DCs to secrete IL-12 upon activation, while strongly enhancing IL-10 production, and promotes DC apoptosis (Penna and Adorini, 2000) . Rapamycin has also been reported to induce apoptosis specifically in DCs but not in monocytes/macrophages (Woltman et al., 2001) . Dexamethasone selectively inhibits differentiation of cord blood stem cell derived-DC precursors into immature DCs and selectively induces apoptosis of developing DCs (Mainali and Tew, 2004) . All of these studies clearly establish that DCs are one of primary targets of many immunosuppressive drugs.
Our data indicate that BA induces selective apoptosis in immature DCs possibly through mitochondria-mediated pathway, suggesting a novel mechanism of immunomodulation by BA which may account, at least in part, for the immunosuppressive effects observed in the animal models and in clinical settings. The fact that BA, next to the antiproliferative effect on T cells, selectively induces apoptosis in immature DCs suggests that BA may have potential applications as a supportive treatment for autoimmunemediated diseases. were found more sensitive for BA-induced apoptosis than mature DC. Concordantly, BA induced more profound change of ∆ψ m in immature DCs than in mature DCs, suggesting BA promote apoptosis through mitochondria-mediated pathway in DCs. A recent study investigated the effects of BA on apoptotic changes in multiple organs of severe acute pancreatitis rats. The results indicated that the apoptosis indexes significantly increased in lymph nodes and spleen in BA-treated group (Tian et al., 2009 ). Therefore, BA-induced DC apoptosis and the importance in vivo warrant further investigation.
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